New HIV vaccine candidates show promise in monkeys

NewsGuard 100/100 Score

"The quest for a vaccine against AIDS is gaining momentum, with research published Wednesday identifying promising new candidates that protected monkeys against a powerful strain of the virus and that soon could be tested in humans," the Wall Street Journal reports (McKay, 1/5). Researchers treated different groups of rhesus monkeys with several different two-stage vaccine combinations and then exposed them to a simian immunodeficiency virus (SIV) that was different than the one used to make the vaccines, according to Nature (Callaway, 1/4).

"The experimental vaccine regimens reduced the monkeys' likelihood of becoming infected per exposure to SIV by 80 to 83 percent compared to a placebo vaccine regimen. Further, in those monkeys that did become infected, the experimental vaccine regimens substantially reduced the amount of virus in the blood compared to controls," an NIH press release states (1/4). "The researchers plan to test that combination in people 'in the near future,'" Dan Barouch, a professor of medicine at Harvard's Beth Israel Deaconess Medical Center who led the study, said, Bloomberg reports (Bennett, 1/4).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    MSU team creates a promising vaccine candidate for antibiotic-resistant bacteria